Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q
Published in Frontiers in Pharmacology
Methodology
Systematic review and meta-analysis of randomised clinical trials using berberine monotherapy for type 2 diabetes, hyperlipidaemia, obesity and related metabolic disorders, including adverse-event reporting.
Key Findings
Berberine monotherapy significantly improved fasting glucose, HbA1c, total cholesterol, LDL and triglycerides, with adverse events largely limited to mild gastrointestinal complaints.
Conclusions
Berberine alone is effective across several metabolic endpoints with an acceptable short-term safety profile.
Limitations
Heterogeneous doses and durations; predominance of small Chinese trials; long-term safety data lacking.
Supplements Studied
Berberine alone significantly improved glycaemic and lipid parameters, with adverse events largely limited to mild gastrointestinal complaints.
Outcomes Measured
Berberine alone significantly improved glycaemic and lipid parameters with an acceptable short-term safety profile.
Berberine alone significantly improved total cholesterol, LDL and triglyceride levels across metabolic disorder trials.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic and provincial research funding
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.